Graft versus Host Disease (GVHD)
Showing 1 - 25 of >10,000
Chronic GVHD, Allogeneic Stem Cell Transplant Trial in Boston (App, Usual Care)
Recruiting
- Chronic Graft-Versus-Host Disease
- Allogeneic Stem Cell Transplant
- App
- Usual Care
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Jan 24, 2023
GVHD,Acute, GVHD, Chronic Trial in Salamanca (Physical exercise)
Recruiting
- GVHD,Acute
- GVHD, Chronic
- Physical exercise
-
Salamanca, SpainUniversity of Salamanca
May 27, 2022
Graft-versus-host Disease Trial in Milwaukee (Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil)
Not yet recruiting
- Graft-versus-host Disease
- Cyclophosphamide
- +3 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Jan 26, 2023
Ocular Surface Disease in Chronic Graft-Versus-Host Disease
Recruiting
- Dry Eye
- GVHD
- Cross-sectional study
-
Singapore, SingaporeCynthia Boo
Mar 22, 2022
Graft-versus-host Disease (GVHD) Trial (Ruxolitinib)
Approved for marketing
- Graft-versus-host Disease (GVHD)
- (no location specified)
Jan 26, 2023
Graft Vs Host Disease Trial in New York (Cyclophosphamide, Abatacept, Tacrolimus)
Recruiting
- Graft Vs Host Disease
- Cyclophosphamide
- +2 more
-
New York, New YorkNYU Langone Health
Nov 10, 2022
Graft-versus-host Disease Trial in New York (Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention)
Active, not recruiting
- Graft-versus-host Disease
- Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
-
New York, New YorkNYU Langone Health
Aug 5, 2022
Graft-versus-host Disease Trial in New York (Cyclophosphamide, Abatacept, Bortezomib)
Recruiting
- Graft-versus-host Disease
- Cyclophosphamide
- +2 more
-
New York, New YorkNYU Langone Health
Mar 24, 2022
A PMS of Jakavi® in Steroid-Refractory Graft-versus-Host Disease
Not yet recruiting
- Graft-versus-Host Disease
- ruxolitinib
- (no location specified)
Jan 11, 2023
GVHD Trial (VM-001 1X10^6 cells/kg, VM-001 3X10^6 cells/kg, VM-001 5X10^6 cells/kg)
Not yet recruiting
- Graft Versus Host Disease
- VM-001 1X10^6 cells/kg
- +4 more
- (no location specified)
Mar 2, 2022
GVHD, GVHD, Undefined Trial in United States (Photobiomodulation Therapy, Placebo sham device)
Recruiting
- Graft-Versus-Host Disease
- +2 more
- Photobiomodulation Therapy
- Placebo sham device
-
Bethesda, Maryland
- +8 more
Jan 17, 2023
Hematopoietic Stem Cell Transplantation, Acute GVHD, Acute Myeloid Leukemia Trial in United States (CD24Fc, Placebo,
Terminated
- Hematopoietic Stem Cell Transplantation
- +4 more
- CD24Fc
- +3 more
-
Duarte, California
- +3 more
Oct 18, 2022
Acute GVHD (Gvhd) Grade, Hematopoietic Cell Transplantation, Fecal Microbiota Transplant Trial in Boston (Fecal Microbiota
Recruiting
- Acute Graft-Versus-Host Disease (Gvhd) Grade
- +2 more
- Fecal Microbiota Transplant
-
Boston, MassachusettsMassachusetts General Hospital
Sep 29, 2021
GVHD Trial in Chicago (Expressive Writing)
Not yet recruiting
- Graft Versus Host Disease
- Expressive Writing
-
Chicago, IllinoisDepartment of Dermatology, Northwestern University Feinberg Scho
Jan 12, 2023
GVHD, Postbiotics, Butyrate Trial in Seoul (sodium butyrate)
Recruiting
- Graft Versus Host Disease
- +2 more
- sodium butyrate
-
Seoul, Korea, Republic ofSoonchunhyang University Seoul Hospital
Apr 11, 2023
Acute Graft Versus Host Disease
Not yet recruiting
- GVHD,Acute
- blood sample
-
Detroit, MichiganHenry Ford Health System
Jan 30, 2023
Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease Trial in Boston (Exercise, Attention
Recruiting
- Graft Vs Host Disease
- +2 more
- Exercise
- Attention control
-
Boston, Massachusetts
- +1 more
Nov 28, 2022
Acute GVHD Trial (MTX, Corticosteroid)
Not yet recruiting
- Acute Graft Versus Host Disease
- (no location specified)
Jun 26, 2023
HIV, Hematologic Malignancies Trial run by the National Cancer Institute (NCI) (RIC, GVHD prophylaxis, allo HCT)
Not yet recruiting
- HIV
- Hematologic Malignancies
- RIC
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism Trial in Belgium, Netherlands (Mesenchymal stem
Recruiting
- Graft-versus-host Disease
- +2 more
- Mesenchymal stem cells
-
Edeghem, Antwerpen, Belgium
- +11 more
Sep 19, 2022
Allogeneic Disease, GVH - Graft Versus Host Reaction, GVHD, Acute Trial in Paris (Methotrexate, Placebo)
Recruiting
- Allogeneic Disease
- +3 more
- Methotrexate
- Placebo
-
Paris, FranceSaint Antoine Hospital - Hematology Department
Oct 22, 2021